News
Breaking!!! Study Indicates Oxford Coronavirus Vaccine Produces Strong Immune Response
- A group Scientists at Oxford University has taken critical step towards discovering an effective Coronavirus Vaccine.
- The result in the first phase induces strong immune response.
- The Vaccine can produce a T cell response within 14 days after vaccination and an antibody response within 28 days
A team of scientists at Oxford University’s Jenner Institute and Oxford Vaccine Group have taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
The results of the Phase I/II trial published on Monday in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses in both parts of the immune system.
According to the University of Oxford, the vaccine provoked a T cell response within 14 days of vaccination (white blood cells that can attack cells infected with the SARS-CoV-2 virus), and an antibody response within 28 days (antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted).
During the study, participants who received the vaccine had detectable neutralising antibodies, which have been suggested by researchers as important for protection, and those responses were strongest after a booster dose, with 100% of participants’ blood having neutralising activity against the coronavirus. The next step in studying the vaccine is to confirm that it can effectively protect against SARS-CoV-2 infection
The Phase I/II data for the coronavirus vaccine shows that the vaccine did not lead to any unexpected reactions and had a similar safety profile to previous vaccines of the same kind. The immune responses observed following vaccination were in line with what previous animal studies have shown are associated with protection against the SARS-CoV-2 virus. The scientists stated they must continue with continue with rigorous clinical trial programme to confirm this in human.
A UK Phase I/II trial began in April testing the Oxford coronavirus vaccine ChAdOx1 nCoV-19. The team started working to develop a vaccine against the global threat, that is, coronavirus in January 2020 and have been working with unprecedented urgency in a race against the coronavirus.
During the Phase I/II trial, the vaccine has been evaluated in more than 1,000 healthy adult volunteers aged between 18 and 55 years in a randomised controlled trial. A subset of these volunteers (10 people) received two doses of the vaccine. Between April 23, 2020 and May 21, 2020, 1077 volunteers, received the vaccine ChAdOx1 nCoV-19 or a placebo MenACWY vaccine. There were no serious adverse health events related to ChAdOx1 nCoV-19.
These encouraging results support further evaluation of the scientists vaccine in our ongoing large scale Phase III programme, that is still needed to assess the ability of the vaccine to protect people from COVID-19
The report disclosed that the University of Oxford is working with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the Covid-19 vaccine, with plans for clinical development and production of the Oxford vaccine progressing globally. The project has been further spurred by £84 million of Government funding to help accelerate the vaccine’s development.
Advertise or Publish a Story on EkoHot Blog:
Kindly contact us at [email protected]. Breaking stories should be sent to the above email and substantiated with pictorial evidence.
Citizen journalists will receive a token as data incentive.
Call or Whatsapp: 0803 561 7233, 0703 414 5611
